PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines Patricia IzettiAgnes HautefeuillePatricia Ashton-Prolla PRECLINICAL STUDIES 20 May 2014 Pages: 783 - 794
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase Wei-Wen ChienSoraya AllasGilles Salles PRECLINICAL STUDIES 15 May 2014 Pages: 795 - 805
In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog Charng Choon WongNagarajan PeriasamyJohnson Stanslas PRECLINICAL STUDIES 31 May 2014 Pages: 806 - 814
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma Kathy ScorsoneLinna ZhangPeter E. Zage PRECLINICAL STUDIES 16 May 2014 Pages: 815 - 824
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Lawrence M. GelbertShufen CaiAlfonso de Dios PRECLINICAL STUDIES Open access 13 June 2014 Pages: 825 - 837
Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules Vijay J. RajaKuan-Hon LimTracey D. Bradshaw PRECLINICAL STUDIES 15 June 2014 Pages: 838 - 850
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology Yingmiao LiuHongyu TianAndrew B. Nixon PRECLINICAL STUDIES Open access 05 July 2014 Pages: 851 - 859
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3) Aya KikuchiTakashi FurutaniKentaro Enjo PRECLINICAL STUDIES 01 July 2014 Pages: 860 - 870
Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models Laura Muñoz-MorenoM. Isabel ArenasAna M. Bajo PRECLINICAL STUDIES 08 July 2014 Pages: 871 - 882
Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines. Pierre LeblondElodie BouletSamuel Meignan PRECLINICAL STUDIES 11 July 2014 Pages: 883 - 892
Resistance mechanisms of cancer cells to the novel vacuolar H+-ATPase inhibitor archazolid B Rebecca HammYoshikazu SugimotoThomas Efferth PRECLINICAL STUDIES 29 July 2014 Pages: 893 - 903
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer Maha HussainMichael A. CarducciJoshi J. Alumkal PHASE I STUDIES 26 April 2014 Pages: 904 - 912
Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error J. G. Coen van HasseltJan H. M. SchellensAlwin D. R. Huitema PHASE I STUDIES 02 May 2014 Pages: 913 - 927
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma Masafumi IkedaShuichiro ShiinaTakuji Okusaka PHASE I STUDIES Open access 15 May 2014 Pages: 928 - 936
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors James M. ClearyCaio Max S. Rocha LimaHope Uronis PHASE I STUDIES 11 June 2014 Pages: 937 - 945
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer Takayasu KurataJunji TsurutaniKazuhiko Nakagawa PHASE I STUDIES 31 May 2014 Pages: 946 - 954
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer Emiliano CalvoVictor J. ChenMartin Sebastian PHASE I STUDIES 20 June 2014 Pages: 955 - 968
A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations E. R. PlimackJ. R. DesaiW. J. Hwu PHASE I STUDIES 31 May 2014 Pages: 969 - 975
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors Gordana VlahovicVassiliki KarantzaMack Mabry PHASE I STUDIES 05 June 2014 Pages: 976 - 984
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients Quentin Chalret du RieuSylvain FouliardMarylore Chenel PHASE I STUDIES 31 May 2014 Pages: 985 - 994
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study Yohann LoriotKarim FizaziJohann S. De Bono PHASE II STUDIES 27 April 2014 Pages: 995 - 1004
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients Anna SpreaficoKim N. ChiSebastien J. Hotte PHASE II STUDIES 03 May 2014 Pages: 1005 - 1016
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group Kristen K. CiomborYang FengJordan Berlin PHASE II STUDIES 04 June 2014 Pages: 1017 - 1027
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies Anna PatrikidouIsabelle SinapiValerie Boige SHORT REPORT 22 April 2014 Pages: 1028 - 1035
Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer Christina A. K. KimJulie Price-HillerJennifer L. Spratlin SHORT REPORT 23 May 2014 Pages: 1036 - 1045
The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report Joseph KattanHampig Raphael Kourie SHORT REPORT 19 July 2014 Pages: 1046 - 1047
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature Angus DalgleishPeter FeatherstoneMoshe Rogosnitzky REVIEW 18 January 2014 Pages: 1048 - 1052